The Associated Press is reporting Schering-Plough and Merck’s recent clinical trial fiasco involving their highly touted anti-cholesterol pill Vytorin, whereby a “European study in patients with heart valve disease found the drug didn’t prevent worsening of the disease or lower the need for valve surgery.”
Such study comes on the heels of a prior analysis which showed that “the medication, which has been on the market since 2004, had little effect on the buildup of plaque in the arteries, a harbinger of heart attack and stroke.”
The significant uncertainty surrounding the efficacy of Vytorin has prompted many health care professionals and patients, to openly question the long-term use of Vytorin as viable cholesterol lowering treatment.
As Dr. Steven Nissen, head of cardiology at the Cleveland Clinic has recently expressed, “This drug doesn’t work. Period. It just doesn’t work.”
If you or someone you know has been adversely affected by Vytorin, please contact our firm immediately for a free consultation